標題
Topics
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Topics
Business
AI & Semiconductor
Taiwan
China
World
Editorial
AI & Semiconductor
China
World
Editorial
AI & Semiconductor
China
World
Editorial
AI & Semiconductor
China
World
Editorial
  1. Home
  2. bispecific antibody

# bispecific antibody  

About 5 search results
Sort by Date
Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311
BusinessPR Newswire

Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311

SHANGHAI
PR Newswire
2026-06-24 08:00
Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026
BusinessPR Newswire

Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026

- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 -
PR Newswire
2026-06-15 19:00
Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors
BusinessPR Newswire

Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI
PR Newswire
2026-06-10 12:06
Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10
BusinessPR Newswire

Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10

SHENZHEN, China
PR Newswire
2026-06-04 18:58
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
BusinessPR Newswire

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

CHICAGO
PR Newswire
2026-05-31 21:00

About Storm Media

The Storm Media (world.storm.mg) is dedicated to bringing Taiwan's voice to the world. We deliver timely, balanced, and internationally oriented reporting and in-depth analysis on key issues including democratic politics, cross-strait relations, geopolitics, Indo-Pacific strategy, technology industry, and economic trends — helping global readers gain a deeper understanding of Taiwan and the Asia-Pacific region.

Brand
The Storm Media (Chinese)
The Storm Media Japan
The Journalist
1% STYLE
Follow
X
Instagram
Facebook
Contact
service@storm.mg
Legal
How We Use AI
Terms of Use
Privacy Policy

About Storm Media

The Storm Media (world.storm.mg) is dedicated to bringing Taiwan's voice to the world. We deliver timely, balanced, and internationally oriented reporting and in-depth analysis on key issues including democratic politics, cross-strait relations, geopolitics, Indo-Pacific strategy, technology industry, and economic trends — helping global readers gain a deeper understanding of Taiwan and the Asia-Pacific region.

The Storm Media (Chinese)
The Storm Media Japan
The Journalist
1% STYLE
Neihu District, Ruiguang Road, Lane 513, No. 37, 4F. Taipei, 114.
X
Instagram
Facebook
service@storm.mg
How We Use AI
Terms of Use
Privacy Policy
Stay True・Look Beyond
Neihu District, Ruiguang Road, Lane 513, No. 37, 4F. Taipei, 114.

Copyright © 2026, Storm Media Group. All rights reserved.

Version: 20260806-141055